Evaluation of the performance of Panbio™ COVID-19 antigen rapid diagnostic test for the detection of SARS-CoV-2 in suspected patients in Ethiopia
- PMID: 35860810
- PMCID: PMC9289906
- DOI: 10.1177/20503121221110079
Evaluation of the performance of Panbio™ COVID-19 antigen rapid diagnostic test for the detection of SARS-CoV-2 in suspected patients in Ethiopia
Abstract
Objective: Reverse transcription-polymerase chain reaction is a gold standard diagnostic tool for coronavirus disease-2019. Limited coverage and long turnaround times are linked to the poor response to the pandemic in developing countries like Ethiopia. To overcome the challenges, rapid antigen diagnostic kits are recommended if their diagnostic performance is at an acceptable level. We explored the performance of the Panbio™ coronavirus disease-2019 antigen rapid diagnostic test in diagnosing the coronavirus disease-2019 infection.
Methods: A cross-sectional study was conducted on coronavirus disease-2019 suspected patients in Wollega University Referral Hospital, from 1 April to 30 May 2021. After obtaining consent/ assent, sociodemographic and pair of nasopharyngeal samples were collected from each and examined by Panbio antigen rapid diagnostic test and reverse transcription-polymerase chain reaction. Data were entered and analysed using SPSS version 24. Sensitivity, specificity, positive and negative predictive values, and kappa values were calculated.
Results: A total of 148 coronavirus disease-2019 suspected individuals (54.1% male) participated in the study. Of all, 73 (49.3%) were positive for severe acute respiratory syndrome corona virus by reverse transcription-polymerase chain reaction test. The sensitivity and specificity of Panbio were found 81% (95% confidence interval: 71%-91%) and 98.7% (95% confidence interval: 96%-100%), respectively. From 75 negative and 73 positive samples by reverse transcription-polymerase chain reaction, 1 (1.33%) and 14 (19.18%) were found false positive and negative by antigen rapid diagnostic test, respectively. Positive predictive value and negative predictive value of Panbio were 98.3% and 84.1%, respectively, and test agreement was substantial (kappa value = 0.80).
Conclusion: Panbio has fine performance in suspected patients. Further studies are needed to examine the accuracy of self-collecting and patient self-testing with healthcare workers, using antigen rapid diagnostic test against the reference standard.
Keywords: COVID-19; diagnostic performance; rapid antigen test; sensitivity; specificity.
© The Author(s) 2022.
Conflict of interest statement
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Evaluation of the performance of Abbott Panbio™ COVID-19 antigen rapid diagnostic test for the detection of severe acute respiratory syndrome coronavirus 2 at Harar, Eastern Ethiopia.Front Med (Lausanne). 2023 May 31;10:1135027. doi: 10.3389/fmed.2023.1135027. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37324158 Free PMC article.
-
The diagnostic performance evaluation of Panbio and STANDARD Q coronavirus disease 2019 antigen tests against real-time polymerase chain reaction in southern Ethiopia.Sci Rep. 2024 Feb 24;14(1):4556. doi: 10.1038/s41598-024-55309-w. Sci Rep. 2024. PMID: 38402333 Free PMC article.
-
[Evaluation of the Rapid Antigen Detection Kit with the Polymerase Chain Reaction for Detection of SARS-CoV-2 in Respiratory Samples].Mikrobiyol Bul. 2022 Apr;56(2):263-273. doi: 10.5578/mb.20229806. Mikrobiyol Bul. 2022. PMID: 35477229 Turkish.
-
Thoracic imaging tests for the diagnosis of COVID-19.Cochrane Database Syst Rev. 2020 Nov 26;11:CD013639. doi: 10.1002/14651858.CD013639.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Mar 16;3:CD013639. doi: 10.1002/14651858.CD013639.pub4. PMID: 33242342 Updated.
-
Thoracic imaging tests for the diagnosis of COVID-19.Cochrane Database Syst Rev. 2020 Sep 30;9:CD013639. doi: 10.1002/14651858.CD013639.pub2. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2020 Nov 26;11:CD013639. doi: 10.1002/14651858.CD013639.pub3. PMID: 32997361 Updated.
References
-
- WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization, 2021, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica... (accessed 2 September 2021).
-
- WHO. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations scientific brief 29 March 2020. World Health Organization, 2021, https://www.who.int/news-room/commentaries/detail/modes-of-transmission-... (accessed 6 September 2021).
LinkOut - more resources
Full Text Sources
Miscellaneous